Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells

Journal of Immunology

Volumn 187, Issue 6, 2011, Pages 3438-3447

  Beum, Paul V ^a   Peek, Elizabeth M ^a   Lindorfer, Margaret A ^a   Beurskens, Frank J ^b   Engelberts, Patrick J ^b   Parren, Paul W H I ^b   Van De Winkel, Jan G J ^b,c   Taylor, Ronald P ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b GENMAB   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; FC RECEPTOR; OFATUMUMAB; RITUXIMAB;

ANIMAL CELL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; B LYMPHOCYTE; CELL FUNCTION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; EFFECTOR CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; INTERNALIZATION; MACROPHAGE; MONOCYTE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TROGOCYTOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CELL LINE; CELL SEPARATION; ENDOCYTOSIS; FLOW CYTOMETRY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; MONOCYTES; RECEPTORS, IGG; TRANSFECTION;

EID: 80053080677     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1101189     Document Type: Article

References (39)

1. Kennedy, A. D., P. V. Beum, M. D. Solga, D. J. DiLillo, M. A. Lindorfer, C. E. Hess, J. J. Densmore, M. E. Williams, and R. P. Taylor. 2004. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J. Immunol. 172: 3280-3288.
2. Williams, M. E., J. J. Densmore, A. W. Pawluczkowycz, P. V. Beum, A. D. Kennedy, M.A. Lindorfer, S.H. Hamil, J. C. Eggleton, andR. P. Taylor. 2006. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J. Immunol. 177: 7435-7443.
3. Beum, P. V., A. D. Kennedy, M. E. Williams, M. A. Lindorfer, and R. P. Taylor. 2006. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J. Immunol. 176: 2600-2609.
4. Beum, P. V., D. A. Mack, A. W. Pawluczkowycz, M. A. Lindorfer, and R. P. Taylor. 2008. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J. Immunol. 181: 8120-8132.
5. Daubeuf, S., M. A. Lindorfer, R. P. Taylor, E. Joly, and D. Hudrisier. 2010. The direction of plasma membrane exchange between lymphocytes and accessory cells by trogocytosis is influenced by the nature of the accessory cell. J. Immunol. 184: 1897-1908.
6. Li, Y., M. E.Williams, J. B. Cousar, A.W. Pawluczkowycz, M. A. Lindorfer, and R. P. Taylor. 2007. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. J. Immunol. 179: 4263-4271.
7. Beers, S. A., R. R. French, H. T. Chan, S. H. Lim, T. C. Jarrett, R. M. Vidal, S. S. Wijayaweera, S. V. Dixon, H. J. Kim, K. L. Cox, et al. 2010. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 115: 5191-5201.
8. Golay, J., E. Cittera, N. Di Gaetano, M. Manganini, M. Mosca, M. Nebuloni, N. van Rooijen, L. Vago, and M. Introna. 2006. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 91: 176-183.
9. Beum, P. V., M. A. Lindorfer, F. Beurskens, P. T. Stukenberg, H. M. Lokhorst, A. W. Pawluczkowycz, P. W. Parren, J. G. van de Winkel, and R. P. Taylor. 2008. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J. Immunol. 181: 822-832.
10. Whipple, E. C., A. H. Ditto, R. S. Shanahan, J. J. Gatesman, S. F. Little, R. P. Taylor, and M. A. Lindorfer. 2007. Low doses of antigen coupled to anti- CR2 mAbs induce rapid and enduring IgG immune responses in mice and in cynomolgus monkeys. Mol. Immunol. 44: 377-388.
11. + cells by rituximab. Blood 101: 1071-1079.
12. Beum, P. V., M. A. Lindorfer, and R. P. Taylor. 2008. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximabopsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J. Immunol. 181: 2916-2924.
13. Beekman, J. M., C. E. van der Poel, J. A. van der Linden, D. L. van den Berg, P. V. van den Berghe, J. G. van de Winkel, and J. H. Leusen. 2008. Filamin A stabilizes FcgRI surface expression and prevents its lysosomal routing. J. Immunol. 180: 3938-3945.
14. Austin, C. D., A. M. De Mazière, P. I. Pisacane, S. M. van Dijk, C. Eigenbrot, M. X. Sliwkowski, J. Klumperman, and R. H. Scheller. 2004. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol. Biol. Cell 15: 5268-5282.
15. Cheson, B. D. 2006. Monoclonal antibody therapy of chronic lymphocytic leukemia. Cancer Immunol. Immunother. 55: 188-196.
16. Hauser, S. L., E. Waubant, D. L. Arnold, T. Vollmer, J. Antel, R. J. Fox, A. Bar- Or, M. Panzara, N. Sarkar, S. Agarwal, et al. 2008. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358: 676-688.
17. Cheson, B. D., and J. P. Leonard. 2008. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N. Engl. J. Med. 359: 613-626.
18. Gürcan, H. M., D. B. Keskin, J. N. Stern, M. A. Nitzberg, H. Shekhani, and A. R. Ahmed. 2009. A review of the current use of rituximab in autoimmune diseases. Int. Immunopharmacol. 9: 10-25.
19. Perosa, F., M. Prete, V. Racanelli, and F. Dammacco. 2010. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. J. Intern. Med. 267: 260-277.
20. Merrill, J. T., and J. P. Buyon. 2010. Rituximab: wanted dead or alive.... Arthritis Rheum. 62: 2188-2191.
21. Østergaard, M., B. Baslund, W. Rigby, B. Rojkovich, C. Jorgensen, P. T. Dawes, C. Wiell, D. J. Wallace, S. C. Tamer, H. Kastberg, et al. 2010. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum. 62: 2227-2238.
22. Davis, T. A., A. J. Grillo-López, C. A. White, P. McLaughlin, M. S. Czuczman, B. K. Link, D. G. Maloney, R. L. Weaver, J. Rosenberg, and R. Levy. 2000. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 18: 3135-3143.
23. Smith, M. R. 2003. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22: 7359-7368.
24. Cartron, G., H. Watier, J. Golay, and P. Solal-Celigny. 2004. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104: 2635-2642.
25. Hainsworth, J. D., S. Litchy, D. W. Shaffer, V. L. Lackey, M. Grimaldi, and F. A. Greco. 2005. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 23: 1088-1095.
26. Martín, A., E. Conde, M. Arnan, M. A. Canales, G. Deben, J. M. Sancho, R. Andreu, A. Salar, P. García-Sanchez, L. Vázquez, et al. 2008. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome: a GEL/ TAMO study. Haematologica 93: 1829-1836.
27. Taylor, R. P., and M. A. Lindorfer. 2010. Antigenic modulation and rituximab resistance. Semin. Hematol. 47: 124-132.
28. Chao, M. P., A. A. Alizadeh, C. Tang, J. H. Myklebust, B. Varghese, S. Gill, M. Jan, A. C. Cha, C. K. Chan, B. T. Tan, et al. 2010. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142: 699-713.
29. Pedersen, A. E., M. B. Jungersen, and C. D. Pedersen. 2011. Monocytes mediate shaving of B-cell-bound anti-CD20 antibodies. Immunology 133: 239-245.
30. Pham, T., P. Mero, and J. W. Booth. 2011. Dynamics of macrophage trogocytosis of rituximab-coated B cells. PLoS One 6: e14498.
31. Iwasaki, S., S. Masuda, T. Baba, U. Tomaru, K. Katsumata, M. Kasahara, and A. Ishizu. 2011. Plasma-dependent, antibody- and Fcγ receptor-mediated translocation of CD8 molecules from T cells to monocytes. Cytometry A 79: 46-56.
32. Schreiber, A. D., and M. M. Frank. 1972. Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. J. Clin. Invest. 51: 575-582.
33. Gong, Q., Q. Ou, S. Ye, W. P. Lee, J. Cornelius, L. Diehl, W. Y. Lin, Z. Hu, Y. Lu, Y. Chen, et al. 2005. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174: 817-826.
34. Glennie, M. J., R. R. French, M. S. Cragg, and R. P. Taylor. 2007. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44: 3823-3837.
35. Taylor, R. P., and M. A. Lindorfer. 2008. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr. Opin. Immunol. 20: 444-449.
36. Ritz, J., J. M. Pesando, S. E. Sallan, L. A. Clavell, J. Notis-McConarty, P. Rosenthal, and S. F. Schlossman. 1981. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood 58: 141-152.
37. Rinnooy Kan, E. A., E. Platzer, K. Welte, and C. Y. Wang. 1984. Modulation induction of the T3 antigen by OKT3 antibody is monocyte dependent. J. Immunol. 133: 2979-2985.
38. Schroff, R. W., R. A. Klein, M. M. Farrell, and H. C. Stevenson. 1984. Enhancing effects of monocytes on modulation of a lymphocyte membrane antigen. J. Immunol. 133: 2270-2277.
39. Schroff, R. W., M. M. Farrell, R. A. Klein, H. C. Stevenson, and N. L. Warner. 1985. Induction and enhancement by monocytes of antibody-induced modulation of a variety of human lymphoid cell surface antigens. Blood 66: 620-626.